Answers are grounded in this paper and cite their sources.
Interim results from the ASTuTE trial demonstrate AI's role in reducing short-term ADT decisions in prostate cancer treatment.
Abstract Short-term androgen deprivation therapy (ST-ADT) improves outcomes for intermediate-risk prostate cancer (IR-PC) but has toxicity. This trial assesses multimodal AI (MMAI) biomarkers in ST-ADT decision-making for men receiving radiotherapy. We report interim results from 200 patients. MMAI testing significantly impacted shared decisions, with 70.3% of patients initially opting for ST-ADT changing decision to forgo ADT (p<0.001). Use of these biomarkers have led to reduced ST-ADT use and better-informed management.
No takes yet. Share an insight, caveat, or question.
Wegener et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: